CN104203282A - 稳定的水性抗体组合物 - Google Patents

稳定的水性抗体组合物 Download PDF

Info

Publication number
CN104203282A
CN104203282A CN201380017932.0A CN201380017932A CN104203282A CN 104203282 A CN104203282 A CN 104203282A CN 201380017932 A CN201380017932 A CN 201380017932A CN 104203282 A CN104203282 A CN 104203282A
Authority
CN
China
Prior art keywords
aqueous solution
alkyl
antibody
mpeg
ethyleneimine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380017932.0A
Other languages
English (en)
Chinese (zh)
Inventor
G·卡西
B·K·德勒姆
J·耶热克
N·罗伊勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arecor Ltd
Original Assignee
Arecor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arecor Ltd filed Critical Arecor Ltd
Publication of CN104203282A publication Critical patent/CN104203282A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Peptides Or Proteins (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
CN201380017932.0A 2012-01-30 2013-01-30 稳定的水性抗体组合物 Pending CN104203282A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261592323P 2012-01-30 2012-01-30
US61/592,323 2012-01-30
PCT/GB2013/050211 WO2013114112A2 (en) 2012-01-30 2013-01-30 Stabilized aqueous antibody compositions

Publications (1)

Publication Number Publication Date
CN104203282A true CN104203282A (zh) 2014-12-10

Family

ID=47681959

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380017932.0A Pending CN104203282A (zh) 2012-01-30 2013-01-30 稳定的水性抗体组合物

Country Status (9)

Country Link
US (2) US10532098B2 (enExample)
EP (1) EP2809350B1 (enExample)
JP (1) JP2015506369A (enExample)
CN (1) CN104203282A (enExample)
CA (1) CA2861402C (enExample)
DK (1) DK2809350T3 (enExample)
ES (1) ES2705538T3 (enExample)
IN (1) IN2014DN06121A (enExample)
WO (1) WO2013114112A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2705538T3 (es) 2012-01-30 2019-03-25 Arecor Ltd Composiciones acuosas de anticuerpo estabilizadas
MX2018009967A (es) * 2016-02-19 2018-11-09 Avery Dennison Corp Metodos en dos etapas para procesar adhesivos y composiciones relacionadas.
GB201613896D0 (en) 2016-08-12 2016-09-28 Arecor Ltd Novel composition
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
WO2020055679A2 (en) * 2018-09-10 2020-03-19 Dow Global Technologies Llc A composition comprising a protein and a polyalkoxy fatty acyl surfactant

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006096461A2 (en) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
WO2011141926A2 (en) * 2010-05-10 2011-11-17 Intas Biopharmaceuticals Limited Liquid formulation of polypeptides containing an fc domain of an immunoglobulin

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
DE19726186A1 (de) 1997-06-20 1998-12-24 Boehringer Ingelheim Int Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
DE19933024C2 (de) 1999-07-15 2003-03-13 Medinnova Ges Med Innovationen Kationische Blockcopolymere
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
US7524938B2 (en) * 2003-04-04 2009-04-28 Yeda Research And Development Co., Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
CA2536120A1 (en) 2003-06-30 2005-02-10 Canji, Inc. Polymer encapsulation of adenoviruses
US7022214B2 (en) 2004-01-21 2006-04-04 Bio-Rad Laboratories, Inc. Carrier ampholytes of high pH range
US20090011004A1 (en) 2005-12-30 2009-01-08 Philadelphia Health & Education Corp., D/B/A/ Drexel University Of College Of Medicine Improved carriers for delivery of nucleic acid agents to cells and tissues
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
US20080312174A1 (en) 2007-06-05 2008-12-18 Nitto Denko Corporation Water soluble crosslinked polymers
CA2737407A1 (en) 2008-09-24 2010-04-01 Stabilitech Ltd. Method for preserving polypeptides using a sugar and polyethyleneimine
AU2009319856A1 (en) * 2008-11-28 2010-06-03 Abbvie Inc. Stable antibody compositions and methods for stabilizing same
US20130209465A1 (en) * 2010-07-30 2013-08-15 Arecor Ltd. Stabilized Aqueous Antibody Compositions
ES2705538T3 (es) 2012-01-30 2019-03-25 Arecor Ltd Composiciones acuosas de anticuerpo estabilizadas

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006096461A2 (en) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
WO2011141926A2 (en) * 2010-05-10 2011-11-17 Intas Biopharmaceuticals Limited Liquid formulation of polypeptides containing an fc domain of an immunoglobulin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHI-CHANG CHEN等: "Spherical aggregates composed of gold nanoparticles", 《NANOTECHNOLOGY》 *

Also Published As

Publication number Publication date
US12016922B2 (en) 2024-06-25
EP2809350B1 (en) 2018-10-17
CA2861402C (en) 2021-10-12
US20200138946A1 (en) 2020-05-07
US10532098B2 (en) 2020-01-14
CA2861402A1 (en) 2013-08-08
IN2014DN06121A (enExample) 2015-08-14
US20150010548A1 (en) 2015-01-08
EP2809350A2 (en) 2014-12-10
JP2015506369A (ja) 2015-03-02
WO2013114112A2 (en) 2013-08-08
WO2013114112A3 (en) 2013-11-07
ES2705538T3 (es) 2019-03-25
DK2809350T3 (en) 2019-01-28

Similar Documents

Publication Publication Date Title
US12016922B2 (en) Stabilized aqueous antibody compositions
US12054555B2 (en) Anti-BAFFR antibody formulations and methods of use thereof
US10588976B2 (en) Anti-CD40 antibody formulation
EP2598167B1 (en) Stabilized aqueous antibody compositions
EP3585360B1 (en) Stabilized antibody solutions
EP3585820A1 (en) Stabilized antibody protein solutions
US20240270864A1 (en) Compositions and methods for injecting particle suspensions
EP4157339A1 (en) Methods of treating iga nephropathy with an april binding antibody
AU2020245573B2 (en) Methods of fingerprinting therapeutic proteins via a two-dimensional (2D) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20141210